Plain-English translation of NCT03686709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is looking at a liver cancer treatment called Y90 radioembolization, which uses tiny radioactive spheres injected directly into tumors to destroy cancer cells. Researchers want to understand how safe this treatment is for both patients receiving it and the medical staff who handle the radioactive material. They'll use special detectors and blood tests to measure radiation exposure during and after the procedure.
While this treatment has shown promise, there are still unanswered questions about radiation safety for the people who give it and the patients who receive it. This study aims to fill that gap by measuring real-time radiation exposure using new monitoring technology, which could help doctors deliver safer, more precise treatment in the future.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive your scheduled cancer treatment as planned, but with additional monitoring. Doctors will place external radiation detectors on your treatment equipment and body during the procedure, and you'll have blood drawn before, during, and after the treatment to measure radiation levels. After treatment, you'll complete an extra PET/CT imaging scan and have a final blood draw—all designed to help researchers better understand how the treatment affects both you and the medical team.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States
Sponsor
University of Tennessee
Collaborators
Biocompatibles UK Ltd
Enrollment target
~20 participants
Started
June 2018
Primary completion
June 2019
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2018.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dustin Osborne, PhD
University of Tennessee
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.